Thymic Carcinoma
Thymic carcinoma is an overtly malignant thymic epithelial tumor of the prevascular (anterior) mediastinum, distinct from thymoma by its frank cytologic atypia, infiltrative growth, high metastatic potential, and characteristic CD5/CD117 (KIT) immunophenotype. Unlike thymoma, thymic carcinoma carries a higher mutational burden (recurrent CDKN2A and TP53 loss, receptor tyrosine kinase pathway alterations including KIT) and generally lacks the autoimmune and paraneoplastic syndromes (e.g., myasthenia gravis, pure red cell aplasia, Good syndrome) that characterize thymoma. It usually presents at an advanced stage and behaves aggressively. Thymic squamous cell carcinoma is by far the most common histologic subtype.
Ask OpenScientist
Ask a research question about Thymic Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Mappings
Subtypes
6Show evidence (1 reference)
Show evidence (1 reference)
Pathophysiology
5Show evidence (2 references)
Show evidence (3 references)
Show evidence (2 references)
Show evidence (1 reference)
Show evidence (1 reference)
Histopathology
1Show evidence (1 reference)
Pathograph
Phenotypes
7Cardiovascular 1
Metabolism 1
Constitutional 1
Growth 1
Other 1
Show evidence (1 reference)
Genetic Associations
4Show evidence (2 references)
Show evidence (2 references)
Show evidence (1 reference)
Show evidence (1 reference)
Medical Actions
7Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (1 reference)
Show evidence (2 references)
Show evidence (1 reference)
Biochemical Markers
1Show evidence (1 reference)
Source YAML
click to showname: Thymic Carcinoma
creation_date: "2026-06-08T00:00:00Z"
description: >-
Thymic carcinoma is an overtly malignant thymic epithelial tumor of the
prevascular (anterior) mediastinum, distinct from thymoma by its frank
cytologic atypia, infiltrative growth, high metastatic potential, and
characteristic CD5/CD117 (KIT) immunophenotype. Unlike thymoma, thymic
carcinoma carries a higher mutational burden (recurrent CDKN2A and TP53 loss,
receptor tyrosine kinase pathway alterations including KIT) and generally
lacks the autoimmune and paraneoplastic syndromes (e.g., myasthenia gravis,
pure red cell aplasia, Good syndrome) that characterize thymoma. It usually
presents at an advanced stage and behaves aggressively. Thymic squamous cell
carcinoma is by far the most common histologic subtype.
category: Neoplastic
categories:
- Thymic epithelial tumor
- Mediastinal neoplasm
- Thoracic cancer
parents:
- thymic epithelial neoplasm
- thymus cancer
- carcinoma
disease_term:
preferred_term: thymic carcinoma
term:
id: MONDO:0006451
label: thymic carcinoma
mappings:
mondo_mappings:
- term:
id: MONDO:0006451
label: thymic carcinoma
mapping_predicate: skos:exactMatch
mapping_source: MONDO
ncit_mappings:
- term:
id: NCIT:C7569
label: Thymus Carcinoma
mapping_predicate: skos:exactMatch
mapping_source: NCIT
notes: >-
Thymic carcinoma is modeled here as a single disease-level mechanism graph
with histologic subtype facets grounded to NCIT, following the same approach
used for the Thymoma entry. Thymic carcinoma is biologically and clinically
distinct from thymoma: it shows overtly malignant epithelial cytology,
CD5/CD117 positivity, a higher mutational burden, greater metastatic
potential, and generally lacks thymoma's autoimmune/paraneoplastic
associations. Thymic neuroendocrine carcinoma is included as a subtype facet
for completeness; many classifications treat thymic neuroendocrine tumors as a
separate category, and this entry scopes it only at the subtype level.
has_subtypes:
- name: Squamous Cell
display_name: Thymic squamous cell carcinoma
classification: histological_pattern
subtype_term:
preferred_term: thymic squamous cell carcinoma
term:
id: NCIT:C6455
label: Thymus Squamous Cell Carcinoma
description: >-
The most common histologic subtype of thymic carcinoma (roughly 70-80% of
cases), composed of overtly malignant keratinizing or non-keratinizing
squamous epithelium that typically expresses CD5 and CD117 (KIT).
evidence:
- reference: PMID:32704057
reference_title: "Preferentially expressed antigen in melanoma as a novel diagnostic marker differentiating thymic squamous cell carcinoma from thymoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Thymic squamous cell carcinoma (TSQCC), accounting for 70-80% of thymic
carcinoma cases, is distinct from thymoma.
explanation: >-
Human tissue study supports thymic squamous cell carcinoma as the
predominant histologic subtype of thymic carcinoma.
- name: Lymphoepithelioma-like
display_name: Lymphoepithelioma-like (lymphoepithelial) carcinoma
classification: histological_pattern
subtype_term:
preferred_term: thymic lymphoepithelial carcinoma
term:
id: NCIT:C7998
label: Thymus Lymphoepithelial Carcinoma
description: >-
Poorly differentiated carcinoma with syncytial epithelial cells in a dense
lymphoplasmacytic background, morphologically resembling nasopharyngeal
lymphoepithelioma; a subset is Epstein-Barr virus associated.
- name: NUT
display_name: NUT carcinoma of the thymus/mediastinum
classification: histological_pattern
subtype_term:
preferred_term: mediastinal/thymus NUT carcinoma
term:
id: NCIT:C146706
label: Mediastinal/Thymus NUT Carcinoma
description: >-
Highly aggressive poorly differentiated carcinoma defined by a NUTM1
rearrangement (most often BRD4-NUTM1), occurring in the thymus/mediastinum
and characterized by abrupt foci of squamous differentiation.
- name: Basaloid
display_name: Basaloid (basaloid squamous cell) carcinoma
classification: histological_pattern
subtype_term:
preferred_term: thymic basaloid squamous cell carcinoma
term:
id: NCIT:C6456
label: Thymus Basaloid Squamous Cell Carcinoma
description: >-
A rare subtype composed of small basaloid cells with peripheral palisading,
high nuclear-to-cytoplasmic ratio, and frequent cystic change.
- name: Sarcomatoid
display_name: Sarcomatoid carcinoma
classification: histological_pattern
subtype_term:
preferred_term: thymic sarcomatoid carcinoma
term:
id: NCIT:C6463
label: Thymus Sarcomatoid Carcinoma
description: >-
A rare, highly aggressive subtype in which the carcinoma shows spindle-cell
or pleomorphic sarcoma-like (mesenchymal) morphology while retaining
epithelial lineage.
- name: Neuroendocrine
display_name: Thymic neuroendocrine carcinoma
classification: histological_pattern
subtype_term:
preferred_term: thymic neuroendocrine carcinoma
term:
id: NCIT:C171031
label: Thymus Neuroendocrine Carcinoma
description: >-
Thymic carcinoma with neuroendocrine differentiation, spanning atypical
carcinoid to small-cell and large-cell neuroendocrine carcinoma. Many
classifications treat thymic neuroendocrine neoplasms as a separate
category; here it is scoped only as a subtype facet of thymic carcinoma.
evidence:
- reference: PMID:37749819
reference_title: "Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Thymic carcinomas (TCs) and thymic neuroendocrine neoplasms (TNENs)
are two aggressive subtypes of thymic malignancy.
explanation: >-
Genomic profiling study supports thymic neuroendocrine neoplasms as a
distinct aggressive thymic malignancy subtype, noted here as a facet with
its own molecular profile.
pathophysiology:
- name: Malignant thymic epithelial transformation
description: >-
Thymic carcinoma arises from malignant transformation of thymic epithelial
cells, producing overtly atypical, invasive epithelium with marked
architectural and cytologic atypia, in contrast to the bland epithelium of
thymoma.
cell_types:
- preferred_term: epithelial cell of thymus
term:
id: CL:0002293
label: epithelial cell of thymus
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
locations:
- preferred_term: thymus
term:
id: UBERON:0002370
label: thymus
evidence:
- reference: PMID:38881813
reference_title: "Insights into molecular aspects and targeted therapy of thymic carcinoma: a narrative review."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Thymic carcinomas are rare tumors derived from thymic
epithelial cells.
explanation: >-
Review establishes thymic carcinoma as a malignancy of thymic epithelial
cell origin.
- reference: PMID:35227908
reference_title: "Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Thymic carcinomas are rare malignancies that in general arise in the
prevascular
explanation: >-
Multidisciplinary review supports thymic carcinoma as a rare malignancy
arising in the prevascular (anterior) mediastinum.
downstream:
- target: CDKN2A and TP53 tumor suppressor loss
description: >-
Transformed thymic epithelium accumulates recurrent tumor suppressor
alterations.
- target: Receptor tyrosine kinase pathway activation
description: >-
Transformed cells engage RTK signaling, including KIT.
- name: CDKN2A and TP53 tumor suppressor loss
description: >-
The most frequent recurrent genomic alterations in thymic carcinoma involve
the tumor suppressors CDKN2A (p16) and TP53, deregulating the G1/S
cell-cycle checkpoint and p53-dependent damage responses and giving thymic
carcinoma a higher mutational burden than thymoma.
gene:
preferred_term: CDKN2A
description: >-
CDKN2A (p16INK4a) loss, often by homozygous deletion, releases the
G1/S checkpoint.
modifier: DECREASED
term:
id: hgnc:1787
label: CDKN2A
gene_products:
- preferred_term: Cyclin-Dependent Kinase Inhibitor 2A
term:
id: NCIT:C17786
label: Cyclin-Dependent Kinase Inhibitor 2A
- preferred_term: Cellular Tumor Antigen p53
term:
id: NCIT:C17387
label: Cellular Tumor Antigen p53
cell_types:
- preferred_term: epithelial cell of thymus
term:
id: CL:0002293
label: epithelial cell of thymus
biological_processes:
- preferred_term: regulation of G1/S transition of mitotic cell cycle
modifier: ABNORMAL
term:
id: GO:2000045
label: regulation of G1/S transition of mitotic cell cycle
- preferred_term: negative regulation of apoptotic process
modifier: INCREASED
term:
id: GO:0043066
label: negative regulation of apoptotic process
evidence:
- reference: PMID:37749819
reference_title: "Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The genetic
alterations that ranked highest in TCs were in CDKN2A, TP53, ASXL1, CDKN2B,
PIK3C2G, PTCH1, and ROS1
explanation: >-
Gene-panel sequencing of thymic carcinoma patients shows CDKN2A and TP53
as the top-ranked recurrent alterations.
- reference: PMID:38881813
reference_title: "Insights into molecular aspects and targeted therapy of thymic carcinoma: a narrative review."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
it suggests that the
frequently involved genes or pathways associated
with thymic carcinoma are tumor suppressor genes, including TP53 and CDKN2A/B,
and the receptor tyrosine kinase pathway.
explanation: >-
Narrative review of thymic carcinoma genomics supports recurrent TP53 and
CDKN2A/B tumor suppressor involvement alongside RTK pathway alterations.
- reference: PMID:37703595
reference_title: "Genomic characterization of thymic epithelial tumors in a real-world dataset."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In the FMI data, CDKN2A (39.9%), TP53
(30.2%) and CDKN2B (24.6%) were frequently altered in thymic carcinoma, versus
TP53 (7.8%), DNMT3A (6.8%), and CDKN2A (5.8%) in thymoma.
explanation: >-
Large real-world genomic dataset quantifies CDKN2A and TP53 as the most
frequent alterations in thymic carcinoma and shows they are far more common
than in thymoma, supporting this tumor-suppressor mechanism node.
downstream:
- target: Aberrant cell-cycle progression and proliferation
description: >-
Loss of G1/S checkpoint control drives uncontrolled proliferation.
- name: Receptor tyrosine kinase pathway activation
description: >-
Receptor tyrosine kinase signaling, including the KIT (CD117) receptor, is
recurrently activated in thymic carcinoma. A subset of squamous cell thymic
carcinomas harbors activating KIT mutations (including exon 17 mutations),
providing oncogenic proliferative and survival signals and a targetable
vulnerability.
gene:
preferred_term: KIT
description: >-
KIT (CD117) receptor tyrosine kinase, recurrently activated and
occasionally mutated in thymic carcinoma.
modifier: INCREASED
term:
id: hgnc:6342
label: KIT
gene_products:
- preferred_term: Mast/Stem Cell Growth Factor Receptor Kit
term:
id: NCIT:C17328
label: Mast/Stem Cell Growth Factor Receptor Kit
cell_types:
- preferred_term: epithelial cell of thymus
term:
id: CL:0002293
label: epithelial cell of thymus
biological_processes:
- preferred_term: Kit signaling pathway
modifier: INCREASED
term:
id: GO:0038109
label: Kit signaling pathway
- preferred_term: cell surface receptor protein tyrosine kinase signaling pathway
modifier: INCREASED
term:
id: GO:0007169
label: cell surface receptor protein tyrosine kinase signaling pathway
evidence:
- reference: PMID:32704057
reference_title: "Preferentially expressed antigen in melanoma as a novel diagnostic marker differentiating thymic squamous cell carcinoma from thymoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
established markers for
TSQCC, including KIT and CD5, which are expressed in ~ 80% of TSQCCs and ~ 3% of
thymomas.
explanation: >-
Immunohistochemical study supports KIT (CD117) expression in ~80% of
thymic squamous cell carcinomas, far exceeding thymoma.
- reference: PMID:35820244
reference_title: "Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Recently, KIT exon 17 mutants turned out
to be a potential molecular target for the type 1 kinase inhibitor avapritinib
(BLU-285).
explanation: >-
Compassionate-use case series supports KIT exon 17 mutations as a
targetable activating alteration in a subset of thymic carcinoma.
downstream:
- target: Aberrant cell-cycle progression and proliferation
description: >-
RTK signaling drives proliferative output in thymic carcinoma cells.
- name: Aberrant cell-cycle progression and proliferation
description: >-
Convergent loss of checkpoint control and gain of RTK signaling drives
sustained, dysregulated proliferation of the malignant thymic epithelium.
cell_types:
- preferred_term: epithelial cell of thymus
term:
id: CL:0002293
label: epithelial cell of thymus
biological_processes:
- preferred_term: regulation of cell cycle
modifier: ABNORMAL
term:
id: GO:0051726
label: regulation of cell cycle
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
evidence:
- reference: PMID:37749819
reference_title: "Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the prognosis-related genes were focused on signal pathways of cell
cycle control, chromatin remodeling/DNA methylation
explanation: >-
Genomic profiling links the recurrent thymic carcinoma alterations to
cell-cycle control pathways governing proliferation.
downstream:
- target: Local invasion and metastatic dissemination
description: >-
Uncontrolled proliferation precedes aggressive invasion and spread.
- name: Local invasion and metastatic dissemination
description: >-
Thymic carcinoma is typically invasive at diagnosis, infiltrating
mediastinal structures and frequently spreading to regional lymph nodes and
distant sites, underlying its aggressive clinical course and poor prognosis
relative to thymoma.
cell_types:
- preferred_term: epithelial cell of thymus
term:
id: CL:0002293
label: epithelial cell of thymus
locations:
- preferred_term: thymus
term:
id: UBERON:0002370
label: thymus
evidence:
- reference: PMID:35227908
reference_title: "Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
These tumors are usually invasive, often present at
advanced stages, and typically behave aggressively.
explanation: >-
Multidisciplinary review supports invasive growth, advanced-stage
presentation, and aggressive behavior as hallmarks of thymic carcinoma.
histopathology:
- name: Overtly malignant epithelial cytology
finding_term:
preferred_term: Thymus Carcinoma
term:
id: NCIT:C7569
label: Thymus Carcinoma
frequency: OBLIGATE
diagnostic: true
description: >-
Thymic carcinoma shows frankly malignant epithelial cytology with marked
atypia and invasive architecture, lacking the organotypic, bland features
of thymoma. The large variety of carcinoma subtypes and absence of a single
unique morphologic/immunophenotypic feature complicate diagnosis.
evidence:
- reference: PMID:35227908
reference_title: "Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Studies are hampered by the
paucity of these tumors, the large variety of carcinoma subtypes, and the lack
of unique morphologic and immunophenotypic features.
explanation: >-
Review supports the morphologic heterogeneity and diagnostic challenge of
thymic carcinoma histopathology.
biochemical:
- name: CD5 and CD117 immunophenotype
biomarker_term:
preferred_term: T-Cell Surface Glycoprotein CD5
term:
id: NCIT:C73124
label: T-Cell Surface Glycoprotein CD5
notes: >-
Coexpression of CD5 and CD117 (KIT) by the neoplastic epithelium is a
characteristic diagnostic immunophenotype that distinguishes thymic
carcinoma (especially the squamous cell subtype) from thymoma, in which
these markers are rarely expressed.
evidence:
- reference: PMID:32704057
reference_title: "Preferentially expressed antigen in melanoma as a novel diagnostic marker differentiating thymic squamous cell carcinoma from thymoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
KIT and
CD5 were positive in 17 (100%) and 16 (94.1%) TSQCCs, respectively, whereas one
(0.9%) type B3 thymoma showed double positivity for KIT and CD5.
explanation: >-
Immunohistochemical series supports CD5/CD117 coexpression as a near-uniform
feature of thymic squamous cell carcinoma that is rare in thymoma.
phenotypes:
- category: Thoracic
name: Anterior mediastinal mass
frequency: OBLIGATE
diagnostic: true
description: >-
Thymic carcinoma characteristically presents as an invasive mass in the
prevascular (anterior) mediastinum.
phenotype_term:
preferred_term: anterior mediastinal mass
term:
id: HP:0033827
label: Anterior mediastinal mass
evidence:
- reference: PMID:35227908
reference_title: "Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Thymic carcinomas are rare malignancies that in general arise in the
prevascular
explanation: >-
Review supports the prevascular (anterior) mediastinal location of thymic
carcinoma masses.
- category: Thoracic
name: Chest pain
frequency: FREQUENT
description: >-
Local invasion of mediastinal and chest-wall structures commonly produces
chest pain.
phenotype_term:
preferred_term: Chest pain
term:
id: HP:0100749
label: Chest pain
- category: Respiratory
name: Dyspnea
frequency: FREQUENT
description: >-
Compression or invasion of airways and adjacent thoracic structures by the
mediastinal tumor causes breathlessness.
phenotype_term:
preferred_term: Dyspnea
term:
id: HP:0002094
label: Dyspnea
- category: Respiratory
name: Cough
frequency: FREQUENT
description: >-
Airway irritation or compression from the mediastinal mass produces cough.
phenotype_term:
preferred_term: Cough
term:
id: HP:0012735
label: Cough
- category: Constitutional
name: Weight loss
frequency: OCCASIONAL
description: >-
Constitutional weight loss occurs as a systemic manifestation of advanced
or metastatic thymic carcinoma.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
- category: Thoracic
name: Pleural effusion
frequency: OCCASIONAL
description: >-
Pleural involvement by locally advanced thymic carcinoma can produce
pleural effusion, a recognized feature of intrathoracic spread.
phenotype_term:
preferred_term: Pleural effusion
term:
id: HP:0002202
label: Pleural effusion
- category: Lymphatic
name: Lymphadenopathy
frequency: OCCASIONAL
description: >-
Regional lymph node involvement (lymphadenopathy) is a feature of thymic
carcinoma's aggressive behavior and metastatic dissemination.
phenotype_term:
preferred_term: Lymphadenopathy
term:
id: HP:0002716
label: Lymphadenopathy
genetic:
- name: CDKN2A loss
gene_term:
preferred_term: CDKN2A
term:
id: hgnc:1787
label: CDKN2A
association: Recurrent somatic tumor suppressor loss
notes: >-
CDKN2A (p16) loss, frequently by homozygous deletion, is among the most
common alterations in thymic carcinoma and deregulates the G1/S checkpoint.
evidence:
- reference: PMID:37749819
reference_title: "Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The genetic
alterations that ranked highest in TCs were in CDKN2A, TP53, ASXL1, CDKN2B,
PIK3C2G, PTCH1, and ROS1
explanation: >-
Sequencing of thymic carcinoma patients ranks CDKN2A among the most
frequent recurrent alterations.
- reference: PMID:37703595
reference_title: "Genomic characterization of thymic epithelial tumors in a real-world dataset."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In the FMI data, CDKN2A (39.9%), TP53
(30.2%) and CDKN2B (24.6%) were frequently altered in thymic carcinoma, versus
TP53 (7.8%), DNMT3A (6.8%), and CDKN2A (5.8%) in thymoma.
explanation: >-
Real-world genomic profiling shows CDKN2A altered in ~40% of thymic
carcinomas versus ~6% of thymomas, supporting CDKN2A loss as a recurrent
driver.
- name: CDKN2B loss
gene_term:
preferred_term: CDKN2B
term:
id: hgnc:1788
label: CDKN2B
association: Recurrent somatic tumor suppressor loss
notes: >-
CDKN2B (p15) is co-located with CDKN2A at 9p21 and is the third most
frequently altered gene in thymic carcinoma, often co-deleted with CDKN2A,
further deregulating the G1/S cell-cycle checkpoint.
evidence:
- reference: PMID:37703595
reference_title: "Genomic characterization of thymic epithelial tumors in a real-world dataset."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In the FMI data, CDKN2A (39.9%), TP53
(30.2%) and CDKN2B (24.6%) were frequently altered in thymic carcinoma, versus
TP53 (7.8%), DNMT3A (6.8%), and CDKN2A (5.8%) in thymoma.
explanation: >-
Real-world genomic profiling ranks CDKN2B as the third most frequent
alteration in thymic carcinoma (24.6%), supporting recurrent CDKN2B loss.
- reference: PMID:38881813
reference_title: "Insights into molecular aspects and targeted therapy of thymic carcinoma: a narrative review."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
it suggests that the
frequently involved genes or pathways associated
with thymic carcinoma are tumor suppressor genes, including TP53 and CDKN2A/B,
and the receptor tyrosine kinase pathway.
explanation: >-
Narrative review supports CDKN2A/B (including CDKN2B) as recurrently
involved tumor suppressors in thymic carcinoma.
- name: TP53 mutation
gene_term:
preferred_term: TP53
term:
id: hgnc:11998
label: TP53
association: Recurrent somatic tumor suppressor mutation
notes: >-
TP53 mutation is a recurrent driver of thymic carcinoma, contributing to its
higher mutational burden and more aggressive biology compared with thymoma.
evidence:
- reference: PMID:38881813
reference_title: "Insights into molecular aspects and targeted therapy of thymic carcinoma: a narrative review."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
it suggests that the
frequently involved genes or pathways associated
with thymic carcinoma are tumor suppressor genes, including TP53 and CDKN2A/B,
and the receptor tyrosine kinase pathway.
explanation: >-
Review of thymic carcinoma genomics supports TP53 as a recurrently
involved tumor suppressor gene.
- name: KIT mutation
gene_term:
preferred_term: KIT
term:
id: hgnc:6342
label: KIT
association: Recurrent somatic oncogenic activation
notes: >-
A minority of thymic carcinomas harbor activating KIT mutations (including
exon 17 mutations), which can confer sensitivity to KIT-directed tyrosine
kinase inhibitors such as avapritinib.
evidence:
- reference: PMID:35820244
reference_title: "Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Recently, KIT exon 17 mutants turned out
to be a potential molecular target for the type 1 kinase inhibitor avapritinib
(BLU-285).
explanation: >-
Case series supports KIT exon 17 mutation as a recurrent, targetable
oncogenic alteration in thymic carcinoma.
treatments:
- name: Complete surgical resection
description: >-
Complete surgical resection (thymectomy with removal of the tumor and
involved structures) is the most effective treatment and the cornerstone of
management for resectable thymic carcinoma.
treatment_term:
preferred_term: thymectomy
term:
id: MAXO:0001079
label: thymectomy
evidence:
- reference: PMID:38881813
reference_title: "Insights into molecular aspects and targeted therapy of thymic carcinoma: a narrative review."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Currently, no
therapy is more effective than complete surgical resection, and the development
of novel therapies, including targeted therapies, is hampered.
explanation: >-
Review supports complete surgical resection as the most effective therapy
for thymic carcinoma.
- name: Radiation therapy
description: >-
Radiation therapy is used adjuvantly after resection and for unresectable or
incompletely resected thymic carcinoma; new radiation techniques are under
evaluation.
treatment_term:
preferred_term: radiation therapy
term:
id: MAXO:0000014
label: radiation therapy
evidence:
- reference: PMID:35227908
reference_title: "Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments From the Thymic Carcinoma Working Group of the International Thymic Malignancy Interest Group."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
advances in diagnostic imaging, surgical approaches, systemic therapies, and
radiation therapy techniques have been made.
explanation: >-
Multidisciplinary review supports radiation therapy as a component of
thymic carcinoma management.
- name: Carboplatin plus paclitaxel chemotherapy
description: >-
Platinum-based chemotherapy, commonly carboplatin plus paclitaxel, is a
standard first-line systemic regimen for advanced, unresectable, or
metastatic thymic carcinoma.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: chemotherapy
term:
id: MAXO:0000647
label: chemotherapy
therapeutic_agent:
- preferred_term: carboplatin
term:
id: CHEBI:31355
label: carboplatin
- preferred_term: paclitaxel
term:
id: CHEBI:45863
label: paclitaxel
evidence:
- reference: PMID:21502559
reference_title: "Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
For patients with thymic carcinoma, no CRs and five
PRs (ORR, 21.7%; 90% CI, 9.0% to 40.4%) were observed; 12 patients had stable
disease.
explanation: >-
Prospective phase 2 trial supports carboplatin plus paclitaxel as an
active first-line regimen for thymic carcinoma.
- name: Lenvatinib
description: >-
Lenvatinib, a multi-targeted tyrosine kinase inhibitor of VEGFR, FGFR, RET,
and c-KIT, is an active second-line option for advanced or metastatic thymic
carcinoma previously treated with platinum-based chemotherapy.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: lenvatinib
term:
id: CHEBI:85994
label: lenvatinib
evidence:
- reference: PMID:32502444
reference_title: "Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
These results suggest that
lenvatinib could become a standard treatment option for patients with previously
treated advanced or metastatic thymic carcinoma.
explanation: >-
The REMORA phase 2 trial supports lenvatinib as a second-line treatment
for advanced or metastatic thymic carcinoma.
- name: Sunitinib
description: >-
Sunitinib, an oral multi-targeted tyrosine kinase inhibitor, is active in
chemotherapy-refractory thymic carcinoma and is used in later lines of
systemic therapy.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: sunitinib
term:
id: CHEBI:38940
label: sunitinib
evidence:
- reference: PMID:25592632
reference_title: "Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Sunitinib is active in previously treated patients with thymic
carcinoma.
explanation: >-
Open-label phase 2 trial supports sunitinib activity in previously treated
thymic carcinoma.
- name: Pembrolizumab
description: >-
Pembrolizumab, an anti-PD-1 monoclonal antibody, shows antitumor activity in
advanced thymic carcinoma after chemotherapy; immune-related adverse events
require careful monitoring.
therapeutic_modality: MONOCLONAL_ANTIBODY
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: pembrolizumab
term:
id: NCIT:C106432
label: Pembrolizumab
evidence:
- reference: PMID:29395863
reference_title: "Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Pembrolizumab is a promising treatment option in patients with
thymic carcinoma.
explanation: >-
Single-arm phase 2 study supports pembrolizumab as an active treatment
option in advanced thymic carcinoma.
- reference: PMID:29395863
reference_title: "Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Because severe autoimmune disorders are more frequent in
thymic carcinoma than in other tumour types, careful monitoring is essential.
explanation: >-
The same trial supports a heightened risk of immune-related adverse events
with checkpoint blockade in thymic carcinoma, warranting careful monitoring.
- name: Avapritinib
description: >-
Avapritinib, a type 1 KIT/PDGFRA inhibitor active against KIT exon 17
mutants, has produced responses in thymic carcinoma harboring KIT exon 17
mutations, illustrating a precision-oncology strategy for the KIT-mutant
subset.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: avapritinib
term:
id: NCIT:C123827
label: Avapritinib
target_mechanisms:
- target: Receptor tyrosine kinase pathway activation
treatment_effect: INHIBITS
description: >-
Avapritinib inhibits KIT exon 17-mutant receptor tyrosine kinase
signaling, the recurrent RTK mechanism in the KIT-mutant subset.
evidence:
- reference: PMID:35820244
reference_title: "Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We describe a differential activity of avapritinib (3/4 patients
responded, 1/4 did not respond)
explanation: >-
Compassionate-use case series supports avapritinib activity in KIT exon
17-mutant thymic carcinoma, targeting the recurrent RTK/KIT mechanism.
references:
- reference: PMID:35227908
title: >-
Thymic Carcinomas-A Concise Multidisciplinary Update on Recent Developments
From the Thymic Carcinoma Working Group of the International Thymic Malignancy
Interest Group.
- reference: PMID:37749819
title: >-
Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms
denote prognosis signatures and pathways.
- reference: PMID:38881813
title: "Insights into molecular aspects and targeted therapy of thymic carcinoma: a narrative review."
- reference: PMID:37703595
title: "Genomic characterization of thymic epithelial tumors in a real-world dataset."
References & Deep Research
References
4Deep Research
11. Disease Information
1.1 What is the disease?
Thymic carcinoma is a malignant epithelial tumor arising in the thymus/anterior mediastinum and is recognized as a distinct entity from thymoma in WHO tumor classifications. (gerber2024epidemiologyofthymomas pages 1-2, kuhn2023thymicepithelialtumors pages 1-2) Its biological behavior differs from thymoma; thymic carcinoma shows “clear malignant potential with often locally advanced or metastatic disease at the time of diagnosis” in contemporary epidemiology-focused reviews. (gerber2024epidemiologyofthymomas pages 1-2)
1.2 Key identifiers (available from retrieved evidence)
| Item type (Ontology/classification) | Identifier/code | Label | Notes (e.g., scope) |
|---|---|---|---|
| Disease classification | — | Thymic carcinoma | Rare malignant epithelial tumor of the thymus; recognized as distinct from thymoma and typically shows more aggressive behavior and malignant potential at diagnosis (gerber2024epidemiologyofthymomas pages 1-2, kuhn2023thymicepithelialtumors pages 1-2) |
| WHO classification | WHO thymic epithelial tumor category | Thymic carcinoma | WHO classifies thymic epithelial tumors into type A, AB, B1-B3 thymomas and thymic carcinomas; thymic carcinoma is the most aggressive major subtype within TETs (kuhn2023thymicepithelialtumors pages 1-2) |
| Histologic subtype note | — | Squamous cell carcinoma (common histology) | Thymic carcinomas are pathologically similar to extrathymic carcinomas and commonly show squamous differentiation; squamous histology accounts for ~70-80% in reviews (gerber2024epidemiologyofthymomas pages 1-2, barachini2023molecularandfunctional pages 2-4) |
| ICD-10 | C37 | Malignant neoplasm of thymus | Broad site-based code covering malignant thymic neoplasms; useful for registry/claims coding but not specific to histologic subtype (supported indirectly by use in thymic malignancy coding and current evidence request) (gerber2024epidemiologyofthymomas pages 1-2) |
| ICD-O-3 topography | C370 | Thymus | Topography code used in Gerber et al. to retrieve anterior mediastinal/thymic tumor registry data (gerber2024epidemiologyofthymomas pages 1-2) |
| ICD-O-3 topography | C379 | Thymus, NOS / unspecified thymic site | Included in registry case retrieval for thymic tumors in epidemiologic analysis (gerber2024epidemiologyofthymomas pages 1-2) |
| ICD-O-3 topography | C381 | Anterior mediastinum | Included in registry retrieval because thymic epithelial tumors arise in the anterior mediastinum (gerber2024epidemiologyofthymomas pages 1-2) |
| Synonym / alternate label | — | Thymic cancer | Common umbrella/clinical term used in epidemiology and review literature; may be less specific than “thymic carcinoma” and can sometimes be used loosely in clinical discourse (gerber2024epidemiologyofthymomas pages 1-2, perrino2023thymicepithelialtumor pages 1-2) |
| Synonym / broader group | — | Thymic epithelial tumor (TET) | Broader category that includes thymomas and thymic carcinomas; thymic carcinoma should not be conflated with thymoma (gerber2024epidemiologyofthymomas pages 1-2, kuhn2023thymicepithelialtumors pages 1-2) |
| Differential classification note | — | Distinct from thymoma | Reviews emphasize that thymic carcinoma differs from thymoma in pathology, prognosis, autoimmune association, and molecular profile (e.g., frequent CDKN2A/TP53 alterations rather than classic thymoma-associated GTF2I pattern) (barachini2023molecularandfunctional pages 1-2, kuhn2023thymicepithelialtumors pages 1-2) |
| MONDO | not retrieved in current evidence | — | No MONDO identifier was retrieved in the available evidence/context set (kuhn2023thymicepithelialtumors pages 1-2, gerber2024epidemiologyofthymomas pages 1-2) |
| Orphanet | not retrieved in current evidence | — | No Orphanet identifier was retrieved in the available evidence/context set (kuhn2023thymicepithelialtumors pages 1-2, gerber2024epidemiologyofthymomas pages 1-2) |
| MeSH | not retrieved in current evidence | — | No MeSH identifier was retrieved in the available evidence/context set (kuhn2023thymicepithelialtumors pages 1-2, gerber2024epidemiologyofthymomas pages 1-2) |
Table: This table summarizes key identifier, synonym, and classification fields for thymic carcinoma using the retrieved evidence. It is useful for normalizing disease labels in a knowledge base while distinguishing thymic carcinoma from broader thymic epithelial tumor categories and from thymoma.
Notes on missing identifiers: MONDO, Orphanet, and MeSH identifiers were not retrievable from the current evidence set and are explicitly flagged as such in the table. (gerber2024epidemiologyofthymomas pages 1-2, kuhn2023thymicepithelialtumors pages 1-2)
1.3 Synonyms / alternative names
Common synonyms include “thymic cancer” and “thymic epithelial tumor (TET)” (the latter as a broader group that includes thymoma and thymic carcinoma). (gerber2024epidemiologyofthymomas pages 1-2, perrino2023thymicepithelialtumor pages 1-2)
1.4 Evidence source type
Key information in this report is derived from: (i) population registries (SEER; German registries), (ii) multicenter/real-world genomics datasets, (iii) single-arm phase II trials and retrospective clinical series, and (iv) society guideline documents (China Anti-Cancer Association). (gerber2024epidemiologyofthymomas pages 1-2, kurokawa2023genomiccharacterizationof pages 1-2, tateishi2024keytherapeuticagents pages 1-2, fang2024chinaanticancerassociation pages 1-2)
2. Etiology
2.1 Disease causal factors
No single specific causal gene or environmental exposure is established as a primary cause for thymic carcinoma; contemporary disease reviews emphasize that thymic carcinomas “do not have a single specific cause” and instead show recurrent somatic alterations and pathway dysregulation typical of carcinogenesis. (barachini2023molecularandfunctional pages 1-2)
2.2 Risk factors
Age/sex (epidemiologic correlates): In a US/Germany registry comparison (1999–2019), mean age at diagnosis for anterior mediastinal tumors including TETs was ~59–61 years, and sex ratios were near‑balanced. (gerber2024epidemiologyofthymomas pages 1-2) SEER-based analysis of thymic carcinoma (2000–2018) reported mean age at thymic carcinoma diagnosis 59.57 ± 13.72 years (median 61). (qiu2024incidenceofsecond pages 1-2)
Autoimmune syndromes: The CACA guideline emphasizes that paraneoplastic syndromes (including myasthenia gravis) are very rare in thymic carcinoma and that if myasthenia gravis is established, the diagnosis should be re-evaluated because the patient may actually have thymoma. (fang2024chinaanticancerassociation pages 2-4)
2.3 Protective factors
No specific protective genetic or environmental factors were identified in the retrieved evidence.
2.4 Gene–environment interactions
No gene–environment interaction evidence specific to thymic carcinoma was identified in the retrieved evidence.
3. Phenotypes
3.1 Common phenotypes and clinical presentation
Thymic carcinoma typically presents as an anterior mediastinal mass with invasive growth; compared with thymoma it more often has locally advanced or metastatic disease at diagnosis. (gerber2024epidemiologyofthymomas pages 1-2, barachini2023molecularandfunctional pages 1-2)
Metastatic pattern (real-world cohort): In a Japanese real-world metastatic thymic carcinoma cohort (n=178), liver metastases were present in 21.9%. (tateishi2024keytherapeuticagents pages 1-2)
3.2 Phenotype characteristics (age of onset, severity, progression, frequency)
- Onset: adult-onset predominance with typical diagnosis around the sixth decade in registry and SEER analyses. (gerber2024epidemiologyofthymomas pages 1-2, qiu2024incidenceofsecond pages 1-2)
- Severity/progression: aggressive course relative to thymoma; CACA guideline describes thymic carcinomas as “rare, aggressive, with worse prognosis than thymomas.” (fang2024chinaanticancerassociation pages 1-2)
3.3 Quality-of-life impact
Direct QoL instrumented measures (EQ‑5D/SF‑36/PROMIS) specific to thymic carcinoma were not identified in the retrieved evidence. Clinically meaningful QoL impact is implied by advanced/metastatic presentations and toxicity risks of systemic therapy. (tateishi2024keytherapeuticagents pages 1-2, thomas2015sunitinibinpatients pages 1-2)
3.4 Suggested HPO terms (non-exhaustive)
- Anterior mediastinal mass (HP:0006714)
- Chest pain (HP:0100749)
- Dyspnea (HP:0002094)
- Cough (HP:0012735)
- Weight loss (HP:0001824)
- Pleural effusion (HP:0002202)
- Lymphadenopathy (HP:0002716)
- Liver metastasis (HP:0031011)
- Bone metastasis (HP:0002667)
(These are ontology term suggestions; frequencies depend on cohort/stage.)
4. Genetic/Molecular Information
4.1 Causal genes
Thymic carcinoma is generally driven by somatic alterations rather than a single causal germline gene in current clinical practice; no established germline causal gene was identified in the retrieved evidence. (barachini2023molecularandfunctional pages 1-2, kurokawa2023genomiccharacterizationof pages 1-2)
4.2 Pathogenic/driver alterations (somatic) and frequencies
Large real-world genomic profiling (2023): In a 794-sample real-world dataset, thymic carcinoma most frequently harbored CDKN2A (39.9%), TP53 (30.2%), and CDKN2B (24.6%) alterations in the US cohort, with similar frequencies in Japan (CDKN2A 38.5%, TP53 36.5%, CDKN2B 30.8%). (kurokawa2023genomiccharacterizationof pages 1-2)
Immuno-oncology genomic biomarkers: TMB‑high (≥10 mutations/Mb) occurred in 7.0% and MSI in 2.3% of thymic carcinomas. (kurokawa2023genomiccharacterizationof pages 1-2) Figure-based visualization of these comparative frequencies versus thymoma is provided in Kurokawa et al. (2023). (kurokawa2023genomiccharacterizationof media 3c301c4f)
Actionable oncogene subset: KIT mutations are described as the most common actionable oncogene but still “only ~10%” in thymic carcinomas in a 2023/2024 review synthesis. (barachini2023molecularandfunctional pages 1-2)
Histotype-associated fusions: Reviews summarize rare subtype-defining fusions including NUT‑BRD4 (NUT carcinoma) and EWSR1‑ATF1 and CRTC1‑MAML2 in selected carcinoma subtypes. (barachini2023molecularandfunctional pages 2-4)
4.3 Modifier genes
No validated modifier genes for thymic carcinoma severity were identified in the retrieved evidence.
4.4 Epigenetic information
Advanced thymic carcinoma may acquire mutations in chromatin/epigenetic regulators per recent reviews, but specific methylation markers were not quantified in retrieved primary datasets. (barachini2023molecularandfunctional pages 1-2)
4.5 Chromosomal abnormalities
Thymic carcinoma shows high molecular complexity among TETs; review-level summaries note genomic complexity and recurrent pathway disruptions but do not provide a single diagnostic chromosomal rearrangement for typical TC. (kuhn2023thymicepithelialtumors pages 1-2)
5. Environmental Information
No specific environmental toxin, occupational exposure, lifestyle factor, or infectious agent was identified as a consistent trigger for thymic carcinoma in the retrieved evidence.
6. Mechanism / Pathophysiology
6.1 Mechanistic overview (causal chain)
A synthesis of contemporary real-world genomics and molecular reviews supports the following chain: 1) Initiating somatic alterations in tumor suppressor/cell-cycle control (notably CDKN2A/CDKN2B loss and TP53 alteration) are common in thymic carcinoma. (kurokawa2023genomiccharacterizationof pages 1-2) 2) These alterations promote cell-cycle dysregulation and genomic instability, consistent with higher relative TMB in thymic carcinoma compared with thymoma and with a subset meeting TMB-high criteria. (kurokawa2023genomiccharacterizationof pages 1-2) 3) Downstream, tumors display invasive growth and metastasis (e.g., liver metastases in ~22% of a metastatic real-world cohort). (tateishi2024keytherapeuticagents pages 1-2) 4) Clinically, this manifests as an aggressive mediastinal malignancy often requiring multimodal therapy and systemic treatment for advanced disease. (gerber2024epidemiologyofthymomas pages 1-2, tateishi2024keytherapeuticagents pages 1-2)
6.2 Key pathways/processes implicated
From metastatic TET sequencing, enriched pathway-level alterations include TP53/CDK, EGFR/RAS, and PI3K/mTOR pathways. (kurokawa2023genomiccharacterizationof pages 1-2)
6.3 Immune system involvement
Thymus biology and immune tolerance raise concerns for immune-related adverse events with immune checkpoint inhibitors (ICIs) in TETs; however, thymic carcinoma appears to have lower severe irAE rates than thymoma in pembrolizumab trials (e.g., grade ≥3 irAEs 15.4% in TC subset in an open-label phase II study). (perrino2023thymicepithelialtumor pages 1-2, silva2025currentclinicalparadigm pages 11-13)
6.4 Suggested ontology terms
GO biological processes (examples): - Cell cycle regulation (GO:0051726) - DNA damage response (GO:0006974) - Angiogenesis (GO:0001525) - Immune evasion / regulation of immune response (e.g., GO:0050776)
Cell Ontology (examples): - Thymic epithelial cell (CL:0002370) - Endothelial cell (CL:0000115) (angiogenesis-targeted therapy context) - T cell (CL:0000084) (tumor immune microenvironment context)
7. Anatomical Structures Affected
7.1 Primary and secondary organs
- Primary site: thymus/anterior mediastinum. (gerber2024epidemiologyofthymomas pages 1-2)
- Common metastatic/secondary sites in advanced disease: pleura/lymph nodes/lung/liver are frequently involved in advanced TET cohorts, and liver metastases are a clinically important subgroup in thymic carcinoma. (cho2019pembrolizumabforpatients pages 2-3, tateishi2024keytherapeuticagents pages 1-2)
7.2 Tissue/cell level
Epithelial malignancy arising from thymic epithelial cells; squamous differentiation is common. (gerber2024epidemiologyofthymomas pages 1-2)
7.3 Suggested UBERON terms
- Thymus (UBERON:0002370)
- Anterior mediastinum (UBERON:0008816)
- Pleura (UBERON:0000977)
- Liver (UBERON:0002107)
- Lymph node (UBERON:0000029)
8. Temporal Development
8.1 Onset
Adult onset predominates; mean/median diagnosis ages are ~59–61 years in registry/SEER analyses. (gerber2024epidemiologyofthymomas pages 1-2, qiu2024incidenceofsecond pages 1-2)
8.2 Progression and staging
Staging is central to prognosis and management. The CACA guideline uses Masaoka–Koga staging in combination with TNM for clinical staging. (tateishi2024keytherapeuticagents pages 1-2)
9. Inheritance and Population
9.1 Epidemiology (recent statistics)
| Domain | Measure | Value | Population/Context | Source (PMID/DOI) | Publication date | URL | Evidence type |
|---|---|---|---|---|---|---|---|
| Epidemiology | Annual incidence, thymic carcinoma | US: 0.48 per million; Germany: 0.42 per million | Population-based registry analysis, 1999-2019 | DOI: 10.3389/fonc.2023.1308989 | 2024-01-09 | https://doi.org/10.3389/fonc.2023.1308989 | Registry epidemiology (gerber2024epidemiologyofthymomas pages 1-2) |
| Epidemiology | Sex ratio and mean age | Male:female ratio 1:1.09/1.03 (US/GER); mean age 59.48 ± 14.89 / 61.33 ± 13.94 years | Adults with thymic carcinoma/thymoma in US and Germany registries | DOI: 10.3389/fonc.2023.1308989 | 2024-01-09 | https://doi.org/10.3389/fonc.2023.1308989 | Registry epidemiology (gerber2024epidemiologyofthymomas pages 1-2) |
| Second malignancy risk | Cohort size | 1,130 thymic carcinoma patients; 73 developed second malignancies | SEER 2000-2018 | DOI: 10.1007/s00432-023-05522-3 | 2024-01 | https://doi.org/10.1007/s00432-023-05522-3 | Registry retrospective (qiu2024incidenceofsecond pages 1-2) |
| Second malignancy risk | Standardized incidence ratio (SIR) | 1.36 (95% CI 1.08-1.69) | Thymic carcinoma patients vs general population | DOI: 10.1007/s00432-023-05522-3 | 2024-01 | https://doi.org/10.1007/s00432-023-05522-3 | Registry retrospective (qiu2024incidenceofsecond pages 1-2) |
| Second malignancy risk | Age-adjusted incidence of second malignancies | 3058.48 per 100,000 persons | Thymic carcinoma patients in SEER | DOI: 10.1007/s00432-023-05522-3 | 2024-01 | https://doi.org/10.1007/s00432-023-05522-3 | Registry retrospective (qiu2024incidenceofsecond pages 1-2) |
| Second malignancy risk | Age at thymic carcinoma diagnosis | Mean 59.57 ± 13.72 years; median 61 years | Thymic carcinoma patients in SEER | DOI: 10.1007/s00432-023-05522-3 | 2024-01 | https://doi.org/10.1007/s00432-023-05522-3 | Registry retrospective (qiu2024incidenceofsecond pages 1-2) |
| Real-world therapy | Carboplatin + paclitaxel (CP) use | Most frequent 1st-line regimen: 85.5% | 178 metastatic thymic carcinoma patients; National Cancer Center Hospital, 2006-2023 | DOI: 10.21873/anticanres.17376 | 2024-12 | https://doi.org/10.21873/anticanres.17376 | Real-world retrospective (tateishi2024keytherapeuticagents pages 1-2) |
| Real-world therapy | CP efficacy | Median PFS 6.8 months; ORR 41.6%; liver metastasis response rate 40.9% | Metastatic thymic carcinoma | DOI: 10.21873/anticanres.17376 | 2024-12 | https://doi.org/10.21873/anticanres.17376 | Real-world retrospective (tateishi2024keytherapeuticagents pages 1-2) |
| Real-world therapy | Lenvatinib efficacy | Median PFS 9.4 months | Metastatic thymic carcinoma | DOI: 10.21873/anticanres.17376 | 2024-12 | https://doi.org/10.21873/anticanres.17376 | Real-world retrospective (tateishi2024keytherapeuticagents pages 1-2) |
| Real-world therapy | Lenvatinib special pattern | Reverse response in liver metastases: 20% | Only liver metastasis increased despite shrinkage elsewhere | DOI: 10.21873/anticanres.17376 | 2024-12 | https://doi.org/10.21873/anticanres.17376 | Real-world retrospective (tateishi2024keytherapeuticagents pages 1-2) |
| Real-world therapy | S-1 use | Most frequent 2nd-line regimen: 58.3% | Metastatic thymic carcinoma | DOI: 10.21873/anticanres.17376 | 2024-12 | https://doi.org/10.21873/anticanres.17376 | Real-world retrospective (tateishi2024keytherapeuticagents pages 1-2) |
| Real-world therapy | S-1 efficacy | Median PFS 4.5 months | Metastatic thymic carcinoma | DOI: 10.21873/anticanres.17376 | 2024-12 | https://doi.org/10.21873/anticanres.17376 | Real-world retrospective (tateishi2024keytherapeuticagents pages 1-2) |
| Real-world therapy | S-1 special pattern | Reverse response in liver metastases: 3.4% | Only liver metastasis increased despite shrinkage elsewhere | DOI: 10.21873/anticanres.17376 | 2024-12 | https://doi.org/10.21873/anticanres.17376 | Real-world retrospective (tateishi2024keytherapeuticagents pages 1-2) |
| Real-world therapy | Sunitinib use | Most frequent 3rd-line regimen: 28.4% | Metastatic thymic carcinoma | DOI: 10.21873/anticanres.17376 | 2024-12 | https://doi.org/10.21873/anticanres.17376 | Real-world retrospective (tateishi2024keytherapeuticagents pages 1-2) |
| Real-world therapy | Sunitinib efficacy | Median PFS 3.4 months | Metastatic thymic carcinoma | DOI: 10.21873/anticanres.17376 | 2024-12 | https://doi.org/10.21873/anticanres.17376 | Real-world retrospective (tateishi2024keytherapeuticagents pages 1-2) |
| Real-world therapy | Sunitinib special pattern | Reverse response in liver metastases: 8.3% | Only liver metastasis increased despite shrinkage elsewhere | DOI: 10.21873/anticanres.17376 | 2024-12 | https://doi.org/10.21873/anticanres.17376 | Real-world retrospective (tateishi2024keytherapeuticagents pages 1-2) |
| Real-world therapy | Cohort characteristics | 78.1% stage IV; 85.4% squamous histology; 21.9% liver metastases | 178 metastatic thymic carcinoma patients | DOI: 10.21873/anticanres.17376 | 2024-12 | https://doi.org/10.21873/anticanres.17376 | Real-world retrospective (tateishi2024keytherapeuticagents pages 1-2) |
| Genomics | Common alterations in thymic carcinoma (FMI cohort) | CDKN2A 39.9%; TP53 30.2%; CDKN2B 24.6% | 794 TET samples overall; FMI real-world cohort | DOI: 10.1016/j.esmoop.2023.101627 | 2023-09-12 (online) | https://doi.org/10.1016/j.esmoop.2023.101627 | Real-world genomics (kurokawa2023genomiccharacterizationof pages 1-2) |
| Genomics | Common alterations in thymic carcinoma (C-CAT cohort) | CDKN2A 38.5%; TP53 36.5%; CDKN2B 30.8% | Japanese C-CAT cohort | DOI: 10.1016/j.esmoop.2023.101627 | 2023-09-12 (online) | https://doi.org/10.1016/j.esmoop.2023.101627 | Real-world genomics (kurokawa2023genomiccharacterizationof pages 1-2) |
| Genomics | TMB-high prevalence | 7.0% | Thymic carcinoma; threshold >=10 mutations/Mb | DOI: 10.1016/j.esmoop.2023.101627 | 2023-09-12 (online) | https://doi.org/10.1016/j.esmoop.2023.101627 | Real-world genomics (kurokawa2023genomiccharacterizationof pages 1-2) |
| Genomics | MSI prevalence | 2.3% | Thymic carcinoma | DOI: 10.1016/j.esmoop.2023.101627 | 2023-09-12 (online) | https://doi.org/10.1016/j.esmoop.2023.101627 | Real-world genomics (kurokawa2023genomiccharacterizationof pages 1-2) |
| Phase II therapy | Sunitinib ORR | 6/23 partial responses = 26% (90% CI 12.1-45.3; 95% CI 10.2-48.4) | Chemotherapy-refractory thymic carcinoma; assessable treated patients | DOI: 10.1016/S1470-2045(14)71181-7 | 2015-02 | https://doi.org/10.1016/S1470-2045(14)71181-7 | Phase II trial (thomas2015sunitinibinpatients pages 4-6, thomas2015sunitinibinpatients pages 1-2) |
| Phase II therapy | Sunitinib additional activity | 9/23 (39%) had tumor shrinkage of 10-30%; median time to response 5.6 months; median response duration 16.4 months | Chemotherapy-refractory thymic carcinoma | DOI: 10.1016/S1470-2045(14)71181-7 | 2015-02 | https://doi.org/10.1016/S1470-2045(14)71181-7 | Phase II trial (thomas2015sunitinibinpatients pages 4-6) |
| Phase II therapy | Sunitinib toxicity | Grade 3/4 lymphocytopenia 20%; fatigue 20%; oral mucositis 20%; LVEF decrease 13% overall, grade 3 in 8%; 1 possible treatment-related cardiac arrest death | 40 treated patients across thymoma + thymic carcinoma cohorts | DOI: 10.1016/S1470-2045(14)71181-7 | 2015-02 | https://doi.org/10.1016/S1470-2045(14)71181-7 | Phase II trial (thomas2015sunitinibinpatients pages 1-2) |
| Phase II / retrospective therapy | S-1 ORR | 42.9% partial response (95% CI 21.4-67.4); DCR 85.7% (60.0-96.0%) | 14 consecutive refractory thymic carcinoma patients | DOI: 10.1186/s12885-016-2159-7 | 2016-02 | https://doi.org/10.1186/s12885-016-2159-7 | Retrospective clinical study (okuma2016correlationbetweens1 pages 1-2) |
| Phase II / retrospective therapy | S-1 survival outcomes | Median PFS 8.1 months (range 2.6-12.2); median OS 30.0 months (range 6.2-41.9) | Refractory thymic carcinoma | DOI: 10.1186/s12885-016-2159-7 | 2016-02 | https://doi.org/10.1186/s12885-016-2159-7 | Retrospective clinical study (okuma2016correlationbetweens1 pages 1-2) |
Table: This table compiles recent high-value quantitative findings for thymic carcinoma across epidemiology, second malignancy risk, real-world treatment outcomes, genomics, and landmark therapeutic studies. It is designed as a compact evidence summary for rapid incorporation into a disease knowledge base.
Key quote (registry abstract): “The overall annual incidence of thymoma was 2.2/2.64 (US/GER) per million inhabitants and for thymic carcinomas 0.48/0.42.” (Gerber et al., published 09 Jan 2024; https://doi.org/10.3389/fonc.2023.1308989). (gerber2024epidemiologyofthymomas pages 1-2)
9.2 Inheritance
No Mendelian inheritance pattern is established for thymic carcinoma in the retrieved evidence; disease is largely sporadic with somatic alterations. (kurokawa2023genomiccharacterizationof pages 1-2, barachini2023molecularandfunctional pages 1-2)
9.3 Population demographics
Gerber et al. report male-to-female ratios close to parity and mean ages around 60 in the US and Germany datasets. (gerber2024epidemiologyofthymomas pages 1-2)
10. Diagnostics
10.1 Clinical tests and imaging
The CACA guideline provides a structured differential diagnostic workflow for anterior mediastinal lesions including enhanced chest CT, MRI, PET/CT, tumor markers (e.g., AFP/β‑HCG), and selected labs (e.g., LDH/CRP/ESR) to distinguish TETs from other mediastinal diseases. (fang2024chinaanticancerassociation pages 2-4)
Key quote (guideline): “PET/CT can be used to evaluate clinical staging of aggressive or locally advanced tumors.” (Fang et al., published Jun 2024; https://doi.org/10.21037/med-23-54). (fang2024chinaanticancerassociation pages 2-4)
10.2 Pathology and immunohistochemistry
- Reviews highlight CD5 and CD117 (KIT) immunohistochemistry as useful markers in thymic carcinoma diagnosis. (barachini2023molecularandfunctional pages 1-2)
- A refractory thymic carcinoma chemotherapy series explicitly notes confirming diagnosis with IHC using CD5 and/or c‑KIT (and TdT to distinguish from thymoma). (okuma2016correlationbetweens1 pages 1-2)
10.3 Molecular testing (omics)
Given frequent alterations in CDKN2A/TP53/CDKN2B and a TMB-high/MSI subset, comprehensive genomic profiling (including TMB/MSI where feasible) is supported for advanced disease to identify therapeutic opportunities. (kurokawa2023genomiccharacterizationof pages 1-2)
10.4 Screening
The CACA guideline states: “CT screening for TETs is not recommended at present” (Recommendation 1B) due to low incidence and lack of evidence of prognostic benefit, but targeted screening by chest CT may be appropriate in selected high-risk contexts (e.g., autoimmune disease such as myasthenia gravis, MEN1). (fang2024chinaanticancerassociation pages 2-4)
11. Outcome/Prognosis
11.1 Survival and mortality
- A thymus/immune-focused review summarizes that thymic carcinoma has worse long-term survival than thymoma and reports 10-year OS ~27% for thymic carcinoma. (perrino2023thymicepithelialtumor pages 1-2)
- The CACA guideline provides stage-stratified survival estimates for thymic carcinoma (stage I–II: 91%; stage III–IV: 31%). (fang2024chinaanticancerassociation pages 1-2)
11.2 Prognostic factors
Stage is consistently emphasized as a dominant prognostic factor. (fang2024chinaanticancerassociation pages 1-2)
11.3 Second malignancies
SEER-based analysis shows elevated risk of second cancers after thymic carcinoma (SIR 1.36) and an age-adjusted second malignancy incidence of 3058.48 per 100,000 persons, supporting survivorship surveillance considerations. (qiu2024incidenceofsecond pages 1-2)
12. Treatment
12.1 Surgery and radiotherapy (real-world implementation)
Resection is standard for resectable disease, with multimodal strategies and adjuvant approaches determined by stage/resection status in guideline frameworks. (tateishi2024keytherapeuticagents pages 1-2, fang2024chinaanticancerassociation pages 1-2)
12.2 Systemic therapy — real-world outcomes (2024)
A large single-center real-world analysis (Japan; metastatic thymic carcinoma; n=178; published Dec 2024) provides practice-facing outcomes: - Carboplatin + paclitaxel (CP): median PFS 6.8 months; ORR 41.6%; liver metastasis response rate 40.9%. (tateishi2024keytherapeuticagents pages 1-2) - Lenvatinib: median PFS 9.4 months; “reverse response” (isolated growth of liver metastases) in 20%. (tateishi2024keytherapeuticagents pages 1-2) - S‑1: median PFS 4.5 months; reverse response 3.4%. (tateishi2024keytherapeuticagents pages 1-2) - Sunitinib: median PFS 3.4 months; reverse response 8.3%. (tateishi2024keytherapeuticagents pages 1-2)
Key quote (abstract): “The median PFS was 6.8, 9.4, 4.5, and 3.4 months in CP, lenvatinib, S‑1, and sunitinib. CP showed an ORR of 41.6%…” (Tateishi et al., 2024; https://doi.org/10.21873/anticanres.17376). (tateishi2024keytherapeuticagents pages 1-2)
12.3 Targeted therapy — authoritative trial evidence
Sunitinib (phase II; Lancet Oncology 2015): In chemotherapy-refractory thymic carcinoma, 6/23 assessable patients achieved partial responses (26%). (thomas2015sunitinibinpatients pages 4-6, thomas2015sunitinibinpatients pages 1-2) The abstract states: “The most common grade 3 and 4 treatment-related adverse events were lymphocytopenia (eight [20%] of 40 patients), fatigue (eight [20%]), and oral mucositis (eight [20%]).” (Thomas et al., 2015; https://doi.org/10.1016/S1470-2045(14)71181-7). (thomas2015sunitinibinpatients pages 1-2)
S‑1 (retrospective series; BMC Cancer 2016): Abstract-reported outcomes include ORR 42.9%, DCR 85.7%, median PFS 8.1 months, and median OS 30.0 months in refractory thymic carcinoma. (Okuma et al., 2016; https://doi.org/10.1186/s12885-016-2159-7). (okuma2016correlationbetweens1 pages 1-2)
12.4 Immunotherapy (ICIs)
While this report prioritized 2023–2024 sources, ICI efficacy/toxicity benchmarks come from phase II studies and are summarized in recent reviews: - Pembrolizumab has reported ORR ~19–23% in previously treated thymic carcinoma cohorts, with lower—but clinically meaningful—grade ≥3 immune-related adverse event rates in thymic carcinoma vs thymoma in a mixed TET phase II trial (15.4% for TC subset). (silva2025currentclinicalparadigm pages 11-13, perrino2023thymicepithelialtumor pages 1-2)
12.5 Current clinical trials (examples; real-world implementation of latest research)
- NCT05832827 (Artemis; first-line): carboplatin/paclitaxel/lenvatinib/pembrolizumab in “previously untreated advanced or recurrent thymic carcinomas” (National Cancer Center, Japan; recruiting). (NCT05832827 chunk 2)
- URL: https://clinicaltrials.gov/study/NCT05832827 (trial registry; 2023). (NCT05832827 chunk 2)
- NCT04710628 (PECATI; pretreated): pembrolizumab + lenvatinib in pre-treated thymic carcinoma patients (MedSIR; phase II record; completed). (NCT04710628 chunk 2)
- URL: https://clinicaltrials.gov/study/NCT04710628 (trial registry; 2021). (NCT04710628 chunk 2)
12.6 Suggested MAXO terms (examples)
- Surgical excision / thymectomy (MAXO:0001174)
- Radiotherapy (MAXO:0000014)
- Platinum-based chemotherapy (MAXO:0000085)
- Tyrosine kinase inhibitor therapy (MAXO:0000757)
- Immune checkpoint inhibitor therapy (MAXO:0000915)
13. Prevention
The CACA guideline states there are no established preventive strategies for mediastinal lesions/TETs and recommends against low-dose CT screening for TETs due to low incidence and lack of evidence of improved prognosis. (fang2024chinaanticancerassociation pages 2-4)
14. Other Species / Natural Disease
No naturally occurring thymic carcinoma evidence in other species, zoonotic considerations, or comparative pathology resources were identified in the retrieved evidence set.
15. Model Organisms
No thymic carcinoma-specific model organism systems (e.g., genetically engineered mouse models, organoids, or canonical cell lines) were identified in the retrieved evidence set.
Visual evidence (genomic landscape)
Kurokawa et al. (ESMO Open, online 12 Sep 2023) provide a figure comparing alteration prevalence and immune-genomic biomarkers between thymic carcinoma and thymoma, supporting the high prevalence of CDKN2A/TP53/CDKN2B alterations and higher TMB-high/MSI frequencies in thymic carcinoma. (kurokawa2023genomiccharacterizationof media 3c301c4f)
Expert opinion and analysis (authoritative sources; integration)
1) Guideline-driven practice is shaped by rarity and differential diagnosis needs: The CACA guideline emphasizes a structured differential diagnostic pathway and cautions against unnecessary surgery for benign incidental lesions, while recommending upfront surgery when high-grade TET (including TC) is suspected. (fang2024chinaanticancerassociation pages 2-4) 2) Precision oncology is increasingly practical: Real-world comprehensive genomic profiling shows reproducible high-frequency alterations (CDKN2A/TP53/CDKN2B) across continents and identifies a non-trivial TMB-high/MSI subset, supporting routine testing when systemic therapy is planned. (kurokawa2023genomiccharacterizationof pages 1-2, kurokawa2023genomiccharacterizationof media 3c301c4f) 3) Real-world outcomes are now quantifiable: Large institutional series (2024) provide regimen-level PFS/ORR benchmarks that complement small single-arm trials and can inform real-world decision-making and trial design. (tateishi2024keytherapeuticagents pages 1-2)
Key data sources (URLs; publication dates)
- Gerber et al. Frontiers in Oncology (Published 09 Jan 2024). https://doi.org/10.3389/fonc.2023.1308989 (gerber2024epidemiologyofthymomas pages 1-2)
- Qiu et al. J Cancer Res Clin Oncol (Jan 2024). https://doi.org/10.1007/s00432-023-05522-3 (qiu2024incidenceofsecond pages 1-2)
- Tateishi et al. Anticancer Research (Dec 2024). https://doi.org/10.21873/anticanres.17376 (tateishi2024keytherapeuticagents pages 1-2)
- Kurokawa et al. ESMO Open (Available online 12 Sep 2023). https://doi.org/10.1016/j.esmoop.2023.101627 (kurokawa2023genomiccharacterizationof pages 1-2)
- Fang et al. Mediastinum (Jun 2024). https://doi.org/10.21037/med-23-54 (fang2024chinaanticancerassociation pages 1-2)
- Thomas et al. Lancet Oncology (Feb 2015). https://doi.org/10.1016/S1470-2045(14)71181-7 (thomas2015sunitinibinpatients pages 1-2)
- Okuma et al. BMC Cancer (2016). https://doi.org/10.1186/s12885-016-2159-7 (okuma2016correlationbetweens1 pages 1-2)
References
-
(gerber2024epidemiologyofthymomas pages 1-2): Tiemo Sven Gerber, Stephanie Strobl, Alexander Marx, Wilfried Roth, and Stefan Porubsky. Epidemiology of thymomas and thymic carcinomas in the united states and germany, 1999-2019. Frontiers in Oncology, Jan 2024. URL: https://doi.org/10.3389/fonc.2023.1308989, doi:10.3389/fonc.2023.1308989. This article has 39 citations.
-
(kurokawa2023genomiccharacterizationof pages 1-2): K. Kurokawa, T. Shukuya, R. Greenstein, B. Kaplan, H. Wakelee, Jonathan J Ross, K. Miura, K. Furuta, S. Kato, J. Suh, S. Sivakumar, E. Sokol, D. P. Carbone, and K. Takahashi. Genomic characterization of thymic epithelial tumors in a real-world dataset. ESMO Open, 8:101627, Oct 2023. URL: https://doi.org/10.1016/j.esmoop.2023.101627, doi:10.1016/j.esmoop.2023.101627. This article has 36 citations and is from a domain leading peer-reviewed journal.
-
(kurokawa2023genomiccharacterizationof media 3c301c4f): K. Kurokawa, T. Shukuya, R. Greenstein, B. Kaplan, H. Wakelee, Jonathan J Ross, K. Miura, K. Furuta, S. Kato, J. Suh, S. Sivakumar, E. Sokol, D. P. Carbone, and K. Takahashi. Genomic characterization of thymic epithelial tumors in a real-world dataset. ESMO Open, 8:101627, Oct 2023. URL: https://doi.org/10.1016/j.esmoop.2023.101627, doi:10.1016/j.esmoop.2023.101627. This article has 36 citations and is from a domain leading peer-reviewed journal.
-
(tateishi2024keytherapeuticagents pages 1-2): AKIKO TATEISHI, YUSUKE OKUMA, YASUSHI GOTO, MOTOKO ARAKAKI, YUKIKO SHIMODA IGAWA, MASAHIRO TORASAWA, YUKI SHINNO, TATSUYA YOSHIDA, HIDEHITO HORINOUCHI, NOBORU YAMAMOTO, and YUICHIRO OHE. Key therapeutic agents for thymic carcinoma in real-world clinical practice. AntiCancer Research, 44:5501-5513, Dec 2024. URL: https://doi.org/10.21873/anticanres.17376, doi:10.21873/anticanres.17376. This article has 2 citations and is from a peer-reviewed journal.
-
(kuhn2023thymicepithelialtumors pages 1-2): Elisabetta Kuhn, Carlo Pescia, Paolo Mendogni, Mario Nosotti, and Stefano Ferrero. Thymic epithelial tumors: an evolving field. Life, 13:314, Jan 2023. URL: https://doi.org/10.3390/life13020314, doi:10.3390/life13020314. This article has 17 citations.
-
(barachini2023molecularandfunctional pages 2-4): Serena Barachini, Eleonora Pardini, Irene Sofia Burzi, Gisella Sardo Infirri, Marina Montali, and Iacopo Petrini. Molecular and functional key features and oncogenic drivers in thymic carcinomas. Cancers, 16:166, Dec 2023. URL: https://doi.org/10.3390/cancers16010166, doi:10.3390/cancers16010166. This article has 7 citations.
-
(perrino2023thymicepithelialtumor pages 1-2): Matteo Perrino, Nadia Cordua, Fabio De Vincenzo, Federica Borea, Marta Aliprandi, Luigi Giovanni Cecchi, Roberta Fazio, Marco Airoldi, Armando Santoro, and Paolo Andrea Zucali. Thymic epithelial tumor and immune system: the role of immunotherapy. Cancers, 15:5574, Nov 2023. URL: https://doi.org/10.3390/cancers15235574, doi:10.3390/cancers15235574. This article has 16 citations.
-
(barachini2023molecularandfunctional pages 1-2): Serena Barachini, Eleonora Pardini, Irene Sofia Burzi, Gisella Sardo Infirri, Marina Montali, and Iacopo Petrini. Molecular and functional key features and oncogenic drivers in thymic carcinomas. Cancers, 16:166, Dec 2023. URL: https://doi.org/10.3390/cancers16010166, doi:10.3390/cancers16010166. This article has 7 citations.
-
(fang2024chinaanticancerassociation pages 1-2): Wentao Fang, Zhentao Yu, Chun Chen, Gang Chen, Keneng Chen, Jianhua Fu, Yongtao Han, Xiaolong Fu, Jie Wang, Teng Mao, Zhitao Gu, and Ning Xu. China anti-cancer association guidelines for the diagnosis, treatment, and follow-up of thymic epithelial tumors (2023). Jun 2024. URL: https://doi.org/10.21037/med-23-54, doi:10.21037/med-23-54. This article has 6 citations.
-
(qiu2024incidenceofsecond pages 1-2): Guanghao Qiu, Fuqiang Wang, and Yun Wang. Incidence of second malignancies in patients with thymic carcinoma and thymic neuroendocrine tumor. Journal of Cancer Research and Clinical Oncology, Jan 2024. URL: https://doi.org/10.1007/s00432-023-05522-3, doi:10.1007/s00432-023-05522-3. This article has 6 citations and is from a peer-reviewed journal.
-
(fang2024chinaanticancerassociation pages 2-4): Wentao Fang, Zhentao Yu, Chun Chen, Gang Chen, Keneng Chen, Jianhua Fu, Yongtao Han, Xiaolong Fu, Jie Wang, Teng Mao, Zhitao Gu, and Ning Xu. China anti-cancer association guidelines for the diagnosis, treatment, and follow-up of thymic epithelial tumors (2023). Jun 2024. URL: https://doi.org/10.21037/med-23-54, doi:10.21037/med-23-54. This article has 6 citations.
-
(thomas2015sunitinibinpatients pages 1-2): Anish Thomas, Arun Rajan, Arlene Berman, Yusuke Tomita, Christina Brzezniak, Min-Jung Lee, Sunmin Lee, Alexander Ling, Aaron J Spittler, Corey A Carter, Udayan Guha, Yisong Wang, Eva Szabo, Paul Meltzer, Seth M Steinberg, Jane B Trepel, Patrick J Loehrer, and Giuseppe Giaccone. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. The Lancet. Oncology, 16 2:177-86, Feb 2015. URL: https://doi.org/10.1016/s1470-2045(14)71181-7, doi:10.1016/s1470-2045(14)71181-7. This article has 352 citations.
-
(silva2025currentclinicalparadigm pages 11-13): Douglas Dias e Silva, Beatriz Viesser Miyamura, Isa Mambetsariev, Jeremy Fricke, Javier Arias-Romero, Amit A. Kulkarni, Ajaz Khan, Debora S. Bruno, Jyoti Malhotra, Abigail Fong, Jae Kim, Colton Ladbury, Arya Amini, Gustavo Schvartsman, and Ravi Salgia. Current clinical paradigm and therapeutic advancements in thymic malignancies: a narrative review. Cancers, 17:3622, Nov 2025. URL: https://doi.org/10.3390/cancers17223622, doi:10.3390/cancers17223622. This article has 1 citations.
-
(cho2019pembrolizumabforpatients pages 2-3): Jinhyun Cho, Hae Su Kim, Bo Mi Ku, Yoon-La Choi, Razvan Cristescu, Joungho Han, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, and Myung-Ju Ahn. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase ii trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37:JCO2017773184, Aug 2019. URL: https://doi.org/10.1200/jco.2017.77.3184, doi:10.1200/jco.2017.77.3184. This article has 374 citations.
-
(thomas2015sunitinibinpatients pages 4-6): Anish Thomas, Arun Rajan, Arlene Berman, Yusuke Tomita, Christina Brzezniak, Min-Jung Lee, Sunmin Lee, Alexander Ling, Aaron J Spittler, Corey A Carter, Udayan Guha, Yisong Wang, Eva Szabo, Paul Meltzer, Seth M Steinberg, Jane B Trepel, Patrick J Loehrer, and Giuseppe Giaccone. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. The Lancet. Oncology, 16 2:177-86, Feb 2015. URL: https://doi.org/10.1016/s1470-2045(14)71181-7, doi:10.1016/s1470-2045(14)71181-7. This article has 352 citations.
-
(okuma2016correlationbetweens1 pages 1-2): Yusuke Okuma, Yukio Hosomi, Shingo Miyamoto, Masahiko Shibuya, Tatsuru Okamura, and Tsunekazu Hishima. Correlation between s-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. BMC Cancer, Feb 2016. URL: https://doi.org/10.1186/s12885-016-2159-7, doi:10.1186/s12885-016-2159-7. This article has 15 citations and is from a peer-reviewed journal.
-
(NCT05832827 chunk 2): First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis). National Cancer Center, Japan. 2023. ClinicalTrials.gov Identifier: NCT05832827
-
(NCT04710628 chunk 2): Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents. MedSIR. 2021. ClinicalTrials.gov Identifier: NCT04710628
